Rapid ventricular tachycardias associated with cilostazol use.
A 92-year-old woman with normal systolic function had recently begun using the newly approved phosphodiesterase III inhibitor cilostazol when she was admitted with lower-extremity pain. Cilostazol is indicated for patients with intermittent claudication and contraindicated for patients with congestive heart failure. Two days after admission, the patient developed ventricular tachycardia. Cilostazol was discontinued, and shortly thereafter the ventricular tachycardia subsided. In this case, cilostazol was apparently an important predisposing factor for ventricular tachycardia.
Gamssari
Farhad
F
Texas Heart Institute at St. Luke's Episcopal Hospital, Houston 77030, USA.
Mahmood
Hatim
H
Ho
John S
JS
Villareal
Rollo P
RP
Liu
Brant
B
Rasekh
Abdi
A
Garcia
Efrain
E
Massumi
Ali
A
D000368:Aged; D000369:Aged, 80 and over; D000077407:Cilostazol; D005260:Female; D006801:Humans; D007383:Intermittent Claudication / Q000188:drug therapy; D010726:Phosphodiesterase Inhibitors / Q000009:adverse effects*; D017180:Tachycardia, Ventricular / Q000139:chemically induced*; D013777:Tetrazoles / Q000009:adverse effects*; D014665:Vasodilator Agents / Q000009:adverse effects*
D010726:Phosphodiesterase Inhibitors; D013777:Tetrazoles; D014665:Vasodilator Agents; D000077407:Cilostazol